Patents Assigned to LFB Biotechnologies
-
Patent number: 8153124Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fc? receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).Type: GrantFiled: July 14, 2009Date of Patent: April 10, 2012Assignee: LFB BiotechnologiesInventors: Roland Beliard, Dominique Bourel, Amaud Glacet, Christophe de Romeuf, Nicolas Bihoreau, Emmanuel Nony
-
Patent number: 8124078Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fc? receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).Type: GrantFiled: July 14, 2009Date of Patent: February 28, 2012Assignee: LFB BiotechnologiesInventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe de Romeuf, Nicolas Bihoreau, Emmanuel Nony
-
Publication number: 20120041056Abstract: A nucleic acid includes at least 15 nucleotides with a length specifically binding with the human factor VII/VIIa.Type: ApplicationFiled: February 19, 2010Publication date: February 16, 2012Applicant: LFB BIOTECHNOLOGIESInventors: Gerald Perret, Frederic Duconge
-
Publication number: 20120040905Abstract: An affinity substrate for selectively binding a coagulation protein, includes a substrate solid on which nucleic aptamers binding specifically to the coagulation protein are immobilized.Type: ApplicationFiled: February 19, 2010Publication date: February 16, 2012Applicant: LFB BIOTECHNOLOGIESInventors: Gerald Perret, Michel Nogre
-
Publication number: 20120009188Abstract: A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.Type: ApplicationFiled: March 19, 2010Publication date: January 12, 2012Applicant: LFB BIOTECHNOLOGIESInventors: Christian Behrens, Sylvie Jorieux, Abdelhakim Kharrat, Khalil Bouayadi, Philippe Mondon, Celine Monnet-Mars
-
Publication number: 20110311556Abstract: The invention relates to an anti-RhD monoclonal antibody, which is a tetrameric IgG1 immunoglobulin composed of two heavy chains and two light chains, the heavy chain comprising the amino acid sequence SEQ ID No. 2, harboring a phenylalanine residue at position 68, and the light chain comprising the amino acid sequence SEQ ID No. 4.Type: ApplicationFiled: March 5, 2010Publication date: December 22, 2011Applicant: LFB-BiotechnologiesInventors: Christine Gaucher, Sylvie Jorieux, Christophe De Romeuf
-
Publication number: 20110274684Abstract: The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human fact VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the Fc?RIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A.Type: ApplicationFiled: May 10, 2011Publication date: November 10, 2011Applicant: LFB BIOTECHNOLOGIESInventors: Christian BEHRENS, Christine Gaucher, Christophe De Romeuf
-
Patent number: 8038993Abstract: The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human factor VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the Fc?RIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A.Type: GrantFiled: November 2, 2006Date of Patent: October 18, 2011Assignee: LFB BiotechnologiesInventors: Christian Behrens, Christine Gaucher, Christophe De Romeuf
-
Publication number: 20110250702Abstract: The present disclosure relates to peptides isolated from rabbit factor VII and to the use of thereof for the generation of antibodies specifically directed against the latter. The disclosure also relates to the use of antibodies directed against rabbit factor VII for the detection or purification of rabbit factor VII, specifically when said rabbit factor VII is in a biological sample which also contains human factor VII.Type: ApplicationFiled: December 31, 2009Publication date: October 13, 2011Applicant: LFB BIOTECHNOLOGIESInventors: Julien Gras, Annick Sauger
-
Patent number: 8025803Abstract: An ion-exchange chromatography support for reducing the ADAMTS13 amount present in a plasma-derived solution containing human von Willebrand factor. The support includes a large-pore, vinyl polymer-type resin bearing DEAE groups, and a buffer including trisodium citrate, sodium chloride, calcium chloride, glycine and lysine.Type: GrantFiled: July 7, 2008Date of Patent: September 27, 2011Assignee: LFB BiotechnologiesInventors: Francoise Bridey, Roland Schmitthaeusler
-
Publication number: 20110201033Abstract: An immunoglobulin of the G class (IgG) directed against the protective antigen (PA) of the anthrax toxin, includes: a light-chain variable region including an amino-acid sequence having at least 90% amino-acid identity with the sequence SEQ ID No 1 such as defined in the description, and a heavy-chain variable region including an amino-acid sequence having at least 90% amino-acid identity with the sequence SEQ ID No 2 such as defined in the description, characterized in that it consists of an IgG1 or an IgG2.Type: ApplicationFiled: November 28, 2008Publication date: August 18, 2011Applicants: LFB-BIOTECHNOLOGIES, ETAT FRANCAIS REPRESENTE PAR LE DELEGUE GENERAL DE L'ARMEMENTInventors: Philippe Thullier, Christian Behrens
-
Publication number: 20110165613Abstract: The invention relates to a cell clone derived from the MovS6 line, said cell clone expressing a prion protein PrP and being capable of tolerating the replication or propagation of the pathological form PrPsc of said PrP, characterized in that its titre with respect to marker for infection with a non-conventional transmissible agent (NCTA) is stable at least up to the 6th passage.Type: ApplicationFiled: September 4, 2009Publication date: July 7, 2011Applicants: LFB-Biotechnologies, Institut National de la Recherche AgronomiqueInventor: Bruno You
-
Publication number: 20110162094Abstract: Modified factors VII/VIIa with a high stability, nucleic acids encoding such modified factors VII/VIIa, and methods of preparing the same.Type: ApplicationFiled: June 12, 2008Publication date: June 30, 2011Applicant: LFB BIOTECHNOLOGIESInventors: Emmanuel Nony, Sami Chtourou, Nicolas Bihoreau
-
Publication number: 20110151476Abstract: The invention relates to an in vitro method for the in vitro detection and/or titration of a non-conventional transmissible agent (NCTA) or of a protein of pathological conformation, which is a marker for infectiousness related to the NCTA, in a sample, comprising: replication or propagation, in cells in culture, of the NCTA present in the sample, and then repeated incubation with a substrate which allows amplification of the NCTA or of the protein of pathological conformation, nonpathological conformer of the NCTA, before determination of the presence and/or of the amount of the NCTA or of the protein of pathological conformation in the sample.Type: ApplicationFiled: March 25, 2009Publication date: June 23, 2011Applicants: LFB-Biotechnologies, Institut National de la Recherche AgronomiqueInventors: Benoit Flan, bruno You
-
Publication number: 20110097715Abstract: A method for purifying or detecting a target protein present in a solution, includes, before carrying out the actual detection or purification step, a step of contacting the solution with an aptamer binding specifically to the target protein, where the aptamer does not bind to a protein homologous to the target protein that could also be present in the solution.Type: ApplicationFiled: August 13, 2008Publication date: April 28, 2011Applicant: LFB - BIOTECHNOLOGIESInventors: Laurent Siret, Abdessatar Chtourou, Frédéric Dhanaut, Gérald Perret
-
Publication number: 20110097754Abstract: The present disclosure relates to a method for measuring the activated factor VII level in a sample to be tested, including the steps of: a) mixing the test sample with a plasma free of factor VII (FVII) and free of at least another factor selected from among factor VIII (FVIII), factor IX (FIX), and factor XI (FXI), the test sample+plasma having a final FVII+FVIIa concentration of 10 pM to 80 pM; b) adding initiating components from the thrombin generation reaction; c) obtaining a thrombogram when carrying out a thrombin generation test (TGT) on the mixture from step b); d) comparing at least one of the thrombogram parameters from step c) with a homologous parameter obtained from standard thrombograms established on the basis of standard samples, the activated factor VII level of which is known and varies with each standard sample; e) deducing, from step d), an activated factor VII level measurement in the test sample.Type: ApplicationFiled: June 29, 2009Publication date: April 28, 2011Applicant: LFB BIOTECHNOLOGIESInventors: Lysiane Hilbert, Claudin Mazurier, Dominique Grenier
-
Patent number: 7931895Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP).Type: GrantFiled: January 24, 2005Date of Patent: April 26, 2011Assignee: LFB BiotechnologiesInventors: Roland Beliard, Arnaud Glacet, Dominique Bourel, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
-
Publication number: 20100305305Abstract: The purification method includes, starting from a solution selected from (i) a solution containing a mixture of FVIII and FvW, (ii) a solution containing FvW, (iii) a solution derived from a secretion of a non-human animal and (iv) a solution derived from a FVIII-containing plant extract, a step of absorption of FVIII or FvW on an ion-exchange chromatography filter-type membrane.Type: ApplicationFiled: August 28, 2008Publication date: December 2, 2010Applicant: LFB-BIOTECHNOLOGIESInventors: Michel Poulle, Patrick Bonneel
-
Publication number: 20100197578Abstract: There is provided in accordance with the practice of this invention a demannosylated Factor VIII, the immunogenicity of which is substantially decreased or abolished in Human. The modified factor VIII is disclosed together with the modified amino acid sequence, changed by at least one substitution. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory anti-FVIII antibodies.Type: ApplicationFiled: April 21, 2008Publication date: August 5, 2010Applicants: LFB Biotechnologies, Institut National De La Sante Et De La Recherche Medicale-InsermInventors: Abdessatar Sami Chtourou, Sébastien Lacroix-Desmazes, Srinivas Kaveri, Suryasarathi Dasgupta, Jagaadeesh Bayry
-
Publication number: 20100193440Abstract: An ion-exchange chromatography support for reducing the ADAMTS13 amount present in a plasma-derived solution containing human von Willebrand factor. The support includes a large-pore, vinyl polymer-type resin bearing DEAE groups, and a buffer including trisodium citrate, sodium chloride, calcium chloride, glycine and lysine.Type: ApplicationFiled: July 7, 2008Publication date: August 5, 2010Applicant: LFB BIOTECHNOLOGIESInventors: Francoise Bridey, Roland Schmitthaeusler